Kuracid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kuracid

Property Description
Active Ingredient Ranitidine Hydrochloride (a single active compound)
Form Tablet, Capsule, Oral Solution, Solution for Injection
Pharmacological Class Histamine H₂-Receptor Antagonist (H₂-blocker), Antiulcer Agent
General Purpose Reduction of stomach acid secretion
Origin Synthetic Compound (Furan ring derivative)

Kuracid is a synthetic antiulcer agent whose core active substance is Ranitidine Hydrochloride. Its specific classification is as a Histamine H₂-Receptor Antagonist, or H₂-blocker, a pharmacological class whose mechanism of action is recognized for inhibiting normal and meal-stimulated secretion of stomach acid.

This compound's efficacy in managing acid-related conditions is established. This medication works to ease digestive discomfort by reliably suppressing acid production at its source. This mechanism involves the competitive antagonism of the H₂-receptors on the stomach's parietal cells, preventing the chemical cascade that stimulates acid release. Kuracid, as a specific preparation containing Ranitidine, represents a formulation tailored for dependable oral and parenteral delivery.

As a single active ingredient product, Kuracid is exclusively based on the Ranitidine Hydrochloride compound. It is manufactured in multiple dosage form(s), including oral tablets, capsules, and sterile solutions for injection. The general utility of Kuracid is to lower the level of corrosive acid in the stomach. A typical use scenario involves taking the medication to manage recurring heartburn or to create an environment conducive to healing when acid has irritated the lining of the digestive tract.

What side effects are possible with Kuracid?

Possible Side Effects and Safety Information

The safety profile of Kuracid (Ranitidine Hydrochloride) is based on official classifications derived from government regulatory documents, which categorize adverse reactions by frequency and physiological system.

Official Frequency Classification

Adverse reactions are officially categorized in prescribing information based on their estimated occurrence rates:

  • Uncommon: Effects reported in this range typically affect the gastrointestinal system and include abdominal pain, constipation, and nausea.
  • Rare/Very Rare: Reactions reported at lower frequencies include transient and reversible changes in liver function tests, skin rash, and rare instances of severe headache or dizziness.

System-Organ Class Effects

Adverse reactions have been officially documented across multiple physiological systems, including Gastrointestinal Disorders, Nervous System Disorders, Hepatobiliary Disorders, and Blood and Lymphatic System Disorders. Rare reports include effects like reversible blurred vision and certain cardiovascular events (e.g., bradycardia), often associated with specific administration methods.

Serious Adverse Reactions

The regulatory profile explicitly documents rare but serious adverse reactions, which include hepatitis (liver inflammation, sometimes with jaundice), acute pancreatitis, and severe hypersensitivity reactions (e.g., anaphylaxis). Additionally, rare but clinically significant blood count abnormalities, such as agranulocytosis and pancytopenia, are officially listed.

Population and Regulatory Constraints

Specific safety statements are included for certain populations. Reversible mental confusion has been reported primarily in severely ill and elderly patients. Caution is advised for individuals with renal impairment due to reduced clearance. A critical high-level regulatory constraint involves the potential formation of the impurity N-Nitrosodimethylamine (NDMA) in the active substance, which has led to specific regulatory actions by health authorities worldwide.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Kuracid (Ranitidine Hydrochloride) is officially documented to present with Central Nervous System (CNS) effects such as lack of coordination, dizziness, somnolence, and fainting. More severe neurological effects reported in regulatory summaries include reversible mental confusion, agitation, depression, and hallucinations.

The official prescribing information also notes severe or life-threatening manifestations. These include collapse, seizure, trouble breathing, and the inability to be awakened (unconsciousness). Additionally, documented cardiovascular effects encompass various cardiac arrhythmias, specifically tachycardia, bradycardia, and atrioventricular block.

When these critical symptoms occur, official regulatory guidance mandates that individuals immediately contact emergency services (such as 911) or call the Poison Help line. For any suspected overdose, individuals must seek immediate medical attention.

The mandated management of Kuracid overdose is symptomatic and supportive treatment. This approach is required because a specific antidote is not explicitly documented in the regulatory prescribing information. A specific consideration noted is the increased reporting of reversible mental confusion and related neurological effects predominantly in severely ill elderly patients.

Therapeutic Uses of Kuracid

Managing Tissue Damage: Peptic Ulcers and Esophageal Erosion

Kuracid is generally used in conditions involving inflammatory or irritative processes where acid has created erosive tissue damage, such as active gastric and duodenal ulcers and erosive esophagitis. The medication is commonly used to help with these conditions by lowering the acid levels that cause irritation, offering symptomatic support. This supports the healing of damaged tissue. The medication is widely used to manage peptic ulcers and GERD.

Relieving Painful Heartburn and Acid Dyspepsia

This medication is relevant for easing symptoms related to physical discomfort, primarily the burning sensation of heartburn and general acid indigestion. It is applied across domains where additional symptomatic support is needed, contributing to improved comfort during periods of heightened symptoms. The core benefit provides supportive relief and contributes to easing the overall symptom load during symptomatic periods.

Specialized Use and Prophylaxis Against High-Acid Risk

Kuracid is considered relevant in specialized contexts, including the management of severe, rare hypersecretory conditions such as Zollinger-Ellison Syndrome. Furthermore, it is applied in scenarios where additional management of discomfort is required to prevent complications, such as ulcers associated with NSAID use or stress ulcers. Kuracid is relevant for managing risk and protection in situations marked by heightened physiological stress.

“The medication is used to support patients during difficult episodes by easing distressing symptoms.”

Quick Fact: Relief for Acid-Related Discomfort The core benefit provides supportive relief and contributes to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Kuracid

Official regulatory documents strictly define the patient populations permitted, restricted, or prohibited from using Kuracid (Ranitidine).

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents (12 years and older) are the primary approved populations. Pediatric use (1 month to 16 years) is permitted for specific indications, often under specialist supervision.
Populations for whom use is contraindicated Patients with known hypersensitivity to ranitidine or any ingredient in the formulation. Patients with a history of acute porphyria must avoid the medicine.
Age-related eligibility rules Neonates (under one month of age): Safety and efficacy have not been established (Use Not Established).
Condition-specific eligibility rules Impaired Renal Function (creatinine clearance less than 50 mL/min): Use requires caution due to potential for altered drug clearance. Hepatic Dysfunction also requires caution.
Pregnancy and lactation status Pregnancy: Use is recommended only if clearly needed, as the drug crosses the placenta. Lactation: Use is generally not recommended as the drug is secreted into breast milk.
Eligibility-related restrictions The possibility of a gastric malignancy must be excluded before commencing therapy for gastric ulcer symptoms, as the medicine may mask symptoms.

These classifications establish absolute prohibitions (contraindications) and mandate conditional use for patients with compromised organ function, directly defining the official scope of eligibility.

What should I know about interactions with other medicines?

Kuracid Interactions with other medicines and products

The interaction profile of Kuracid (Ranitidine) is governed by two primary effects documented in regulatory labeling: alteration of gastrointestinal acidity and competition for the renal organic cation transport system.

Interactions Affecting Drug Exposure

The reduction of stomach acid may significantly alter the absorption of other medicines, leading to two distinct outcomes:

  • Reduced Exposure: Co-administration with certain agents that require an acidic environment for absorption (such as the antiviral Atazanavir and the antifungal oral Ketoconazole) is documented to result in lower plasma concentrations of the co-administered drug. This also applies to Gefitinib and Erlotinib, which may experience reduced efficacy.
  • Increased Exposure: Conversely, the plasma concentrations of certain benzodiazepines, including Midazolam (oral form) and Triazolam, are officially reported to increase when co-administered with Kuracid.

Transporter-Mediated and Metabolic Interactions

Kuracid is documented to compete with the elimination pathway of specific compounds. This includes competition for the renal organic cation transport system, which officially reduces the excretion of Procainamide, leading to increased plasma levels. Additionally, caution is noted regarding co-administration with coumarin anticoagulants like Warfarin, where official documents report cases of altered prothrombin time.

Timing and Combination Restrictions

While Kuracid's absorption is not significantly impaired by food or antacids, mandatory timing rules may apply to co-administered drugs like Sotorasib or Erlotinib to manage the pH-dependent interaction. The chronic co-administration of Kuracid with Delavirdine is officially designated as not recommended due to the potential for significant reduction in the antiviral agent's exposure.

Mechanism of Action

How Kuracid Works: The Mechanism of Action

Kuracid's core mechanism involves acting as a competitive antagonist against Histamine H2 receptors found on the gastric parietal cells.

This interaction prevents the binding of the natural signaling molecule, histamine, thereby inhibiting the signal driving acid production. The drug modifies the early molecular steps in the gastric acid secretion cascade by diminishing the resulting increase in intracellular cyclic AMP ( cAMP).

Since cAMP is a critical second messenger required to fully activate the acid-secreting pumps ( H^+ / K^+- ATPase), this process results in a reduction in parietal cell activity. The consequence of modulating the histamine pathway is a significant increase in the pH and a corresponding decreased volume of gastric secretion. The resulting reduction in the concentration of hydrochloric acid alters the chemical environment within the stomach.

Dosage and Administration Information

Administration Scope

Category Official Instruction
Route of administration Kuracid is approved for oral intake (tablets, solution/syrup) and parenteral administration via intravenous (IV) or intramuscular (IM) injection.
Dosing schedule The standard adult oral dose for acute treatment is typically 150 mg twice daily (b.i.d.) or 300 mg once daily at bedtime. The maintenance dose is generally 150 mg once daily. Parenteral dosing is often 50 mg every 6 to 8 hours.
Timing in relation to meals (if applicable) Oral forms may be taken with or without food. Once-daily regimens are commonly directed to be taken at night to align with the treatment protocol.
Preparation requirements (if applicable) Effervescent tablets must be fully dissolved in a full glass of water before ingestion. Intravenous bolus administration requires the dose to be diluted and administered slowly over at least five minutes.
Age-group administration rules Pediatric dosing follows a weight-based regimen (mg/kg/day) in divided doses. A specific dosage adjustment is mandated for patients with impaired renal function (Creatinine Clearance <50 mL/min), often reduced to 150 mg once daily.

Instruction Classifications (High-Level)

Classification Description
Administration method type Oral and Parenteral (IV, IM).
Frequency pattern Once daily, Twice daily, Every 6–8 hours, or Continuous infusion.
Use-context constraints Defined as a short-term course (typically 4 to 8 weeks) for acute conditions or a long-term daily regimen for recurrence prevention.

Connection to the overall use protocol (2–4 sentences)

The official instructions establish a precise procedural framework for Kuracid administration by defining the exact routes, standardized dosage amounts, and mandated frequencies. This structure guides the correct delivery of the medicine, from the specific preparation requirements for effervescent tablets and IV solutions to the required dose adjustments based on an individual's kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Mechanism of Action

Research is suggested to involve the blocking of reuptake of both serotonin and norepinephrine. The compound is classified as a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI). This dual action is a subject of ongoing research in relation to Major Depressive Disorder (MDD).


Efficacy and Clinical Outcomes

Major Depressive Disorder (MDD) Studies have explored whether changes in measures related to mood and the frequency of depressive episodes are observed. Research examining this potential association often uses the Hamilton Depression Rating Scale (HDRS) to track changes in symptom severity.

  • Short-Term Studies (2–8 weeks): A two-week RCT evaluated changes in symptoms (HDRS scores) and reported that 72% of participants met the defined endpoint. Other studies over eight weeks have explored changes in scores, and reported a measurable difference for a majority of participants.
  • Long-Term Studies (6–12 months): Evidence remains limited on the long-term changes beyond six months. Trials lasting one year have been conducted to evaluate measures over that time period.

Pain Management Research has also evaluated the compound in studies associated with Fibromyalgia and Chronic Musculoskeletal Pain. Studies examined its use in chronic pain conditions by tracking participant-reported pain scores (e.g., VAS or NRS).

  • Fibromyalgia: An eight-week study reported a decrease in pain scores for 55% of participants.
  • Chronic Musculoskeletal Pain: Clinical studies have examined whether there is an observed change within the first week of use. Trials lasting 12 weeks have explored a potential association with changes in measures of functionality.

Safety and Tolerability Profile

Common Side Effects Observed common effects noted in clinical studies were nausea, dry mouth, insomnia, and dizziness. These effects were frequently reported as mild and were observed to diminish after the first weeks of use in some participants.

  • Sexual Side Effects: Evidence was examined in studies comparing the risk of common sexual side effects to older treatments. Studies on this comparison are ongoing.
  • Blood Pressure: An observed increase in blood pressure has been noted in some patient populations across various trials. Uncontrolled high blood pressure is often listed as a caution in research.

Long-Term Considerations The primary concern explored for long-term use is potential liver toxicity; regular liver function tests are a common protocol in clinical trials.


Comparative Research

Some studies have compared its effect to that of SSRIs in certain populations, focusing on differences in efficacy scores and side-effect profiles. Research has explored whether the combination is associated with an overall quality of life measure. These comparative studies are complex and often show mixed results depending on the specific patient group and outcome measures used.

Key Studies & References

  1. Antidepressant-associated sexual dysfunction in outpatients (Informs comparative safety of SNRIs vs. SSRIs on sexual side effects)

Frequently Asked Questions (FAQ)

Common questions about Kuracid (FAQ)


Q: Is Kuracid the same as other medications for this problem?

Official documents classify Kuracid as a Histamine H2-Receptor Antagonist, often called an H₂-blocker. This pharmacological class works specifically by blocking histamine receptors on the stomach's cells to reduce acid production. This mechanism is distinct from other common anti-acid classes, such as proton pump inhibitors (PPIs).


Q: Can Kuracid make me feel tired or drowsy during the day?

Regulatory information lists side effects related to the nervous system, which include documented cases of dizziness and, in rare instances, severe headache or mental confusion, particularly in elderly or severely ill patients. General fatigue or drowsiness is not designated as a frequently occurring side effect in the official product information.


Q: Is Kuracid appropriate for use if I have kidney issues?

Patients with impaired renal function require caution because official instructions note that Kuracid's clearance from the body may be reduced. This can lead to increased levels of the medicine in the plasma. For this reason, a specific adjustment to the prescribed amount is detailed in the official instructions for individuals with compromised kidney function.


Q: Are there known interactions between Kuracid and common pain relievers?

Regulatory documents note that regular supervision is mentioned for patients taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) concomitantly with Kuracid, particularly for older patients. Official sources focus on managing potential interactions between these types of medicines.


Q: Does taking Kuracid with food change how it works?

The official instructions state that oral forms of the medicine may be taken with or without food. Food is generally described as having no significant effect on the absorption of the drug. Once-daily regimens are often directed to be taken at night to align with the treatment protocol.


Q: Can Kuracid be crushed or split if it is hard to swallow?

Regulatory preparation requirements explicitly state that effervescent tablets must be fully dissolved in water before ingestion. Official documentation does not provide a general instruction regarding crushing or splitting standard Kuracid tablets or capsules.


Q: Does Kuracid cause problems with alcohol consumption?

Official findings examined the combination of Kuracid and alcohol consumed in common amounts, and results indicated no clinically or socially significant interaction. Official sources examine the potential for interaction between these substances.


Q: What happens if a pregnant person takes Kuracid by accident?

Official documentation notes that Kuracid crosses the placenta and is secreted into breast milk. Use during pregnancy is officially stated as being recommended only if the benefit is clearly needed and is judged to outweigh the potential risk. The drug is secreted into breast milk, and its use is generally not recommended during lactation. The regulatory summary does not detail specific factual outcomes of accidental exposure.


Q: How quickly does Kuracid start to work after taking it?

Official sources for the treatment of gastroesophageal reflux disease (GERD) note that symptomatic relief usually occurs within 24 hours after beginning therapy. The drug's action begins upon administration to suppress acid secretion.


Q: What happens if I miss a dose of Kuracid?

Patient information sheets based on official dosing rules advise that a missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Official instructions specify that doses are not to be doubled to compensate for a missed dose.


Q: Are there any common long-term side effects of Kuracid?

Clinical trials have examined long-term use (up to one year) of the medicine. Regulatory documents list a broad range of reactions across body systems, but they do not specifically categorize which of these effects are designated as 'common' after many months of continuous, long-term use.


Q: What is the recommended duration of treatment with Kuracid?

Regulatory documents describe a typical treatment duration of 4 to 8 weeks for treating acute conditions. For the purpose of preventing recurrence, official labeling notes that maintenance therapy has been studied and prescribed for periods of up to one year.


Q: What if Kuracid doesn't seem to be working for me?

Official documents implicitly acknowledge the potential for treatment failure. They note that if a standard prescribed amount is ineffective, the dose is not recommended to be doubled, and the consideration of alternative therapy is noted in the documents.


Q: Can Kuracid cause hair loss or weight changes?

Official reports of adverse effects have included descriptions of hair loss (alopecia) as a rare reaction. Similarly, changes in appetite that could lead to changes in weight have been observed, but these effects are typically documented as rare occurrences in official regulatory summaries.


Q: Does Kuracid affect the ability to drive or operate machinery?

Official documentation states that there have been no reported effects on the patient’s ability to drive or operate machinery while taking Kuracid. However, caution is noted because nervous system effects, such as dizziness and confusion, are listed as potential side effects.


Q: What type of doctor usually prescribes Kuracid?

Prescription-strength Kuracid is typically used to manage more serious conditions, such as ulcers, and is prescribed by a physician or specialist. Lower-strength formulations of the medicine have been widely available over-the-counter for the relief of common heartburn.


Q: Are there different strengths or versions of the Kuracid pill?

Official labeling confirms that the product has been manufactured and approved in several different strengths for oral use, including 75 mg, 150 mg, and 300 mg tablets, capsules, and solutions.


Q: Are there documented cases of Kuracid not working for some people?

Official regulatory documents implicitly acknowledge the potential for non-response. They note that if a standard prescribed amount is ineffective, the dose is not recommended to be doubled, and the consideration of alternative therapy is noted in the documents.


Q: Is Kuracid effective for short-term use only?

Official labeling describes Kuracid's use for both short-term treatment (e.g., 4 to 8 weeks for acute conditions) and for long-term maintenance purposes. Long-term use is specifically studied for up to one year to help prevent the recurrence of symptoms.


Q: Can Kuracid be used alongside other treatments for the main condition?

The official product labeling features a detailed interaction profile focused on managing the co-administration of Kuracid with a range of other medicines. This indicates that it is commonly used in treatment protocols with other therapies, provided potential drug-drug interactions are appropriately managed.


Q: Why is Kuracid not recommended for people under a certain age?

Regulatory documents state that safety and efficacy in neonates (infants under one month of age) have not been established. Pediatric use in older children is permitted for specific indications, but often requires specialist supervision.


Q: Does Kuracid affect blood pressure readings?

Official clinical trial observations have noted an observed increase in blood pressure in some specific patient populations. Due to this potential effect, official research protocols and cautions often list uncontrolled high blood pressure as a factor requiring consideration.


Q: Are there non-drug interactions listed for Kuracid (e.g., sun exposure)?

Clinical literature and safety reports have examined the potential for photosensitivity, which is a skin reaction to sunlight or UV exposure. While not a common finding, this effect has been reported in association with this class of medication.


Q: Why does the official source mention Kuracid can cause dizziness?

Official prescribing information documents dizziness as an uncommon or rare adverse reaction. It is classified under Nervous System Disorders in the safety profile, indicating it is a known effect tied to the body's reaction to the medicine.


Q: Do older adults need a different dose of Kuracid?

Official dosing guidelines do not typically mandate a dose reduction based on age alone. However, dose adjustments are required if impaired renal function is present, which is a condition often found in older adults. Additionally, mental confusion is a rare nervous system side effect reported primarily in severely ill and elderly patients.

How should Kuracid be stored and disposed of?

Storage and Disposal of Kuracid (Ranitidine HCl)

The storage and disposal instructions for Kuracid are determined by a regulatory safety finding. The U.S. Food and Drug Administration (FDA) requested the withdrawal of all ranitidine products from the market because the probable human carcinogen NDMA was found to increase to unacceptable levels over time and especially when stored at higher temperatures.

Classification Status
Storage Status Disposal Mandate
Stability Risk Increased NDMA over time/heat

Consumers were advised to stop taking the medication immediately. The official disposal instruction is to not return the product to a drug take-back site. Instead, mix the medicine with an unappealing substance, place it in a sealed bag, and discard it in the household trash. The medication must be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kuracid found in:

A-Z Index: